Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||FAZ053 + Spartalizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|FAZ053||FAZ-053|FAZ 053||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 62||FAZ053, is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).|
|Spartalizumab||PDR001|PDR-001||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 62||Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02936102||Phase I||FAZ053 FAZ053 + Spartalizumab||A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.||Active, not recruiting|